SLN) presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback